Selected research
Industry Research
Somatostatin Receptor Type 2 Industry Research Report 2026
Market perspective
The global Somatostatin Receptor Type 2 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Somatostatin Receptor Type 2 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Somatostatin Receptor Type 2 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Somatostatin Receptor Type 2 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Somatostatin Receptor Type 2 include Amryt Pharma plc, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Ipsen SA, Progenics Pharmaceuticals Inc, Strongbridge Biopharma plc and Zucara Therapeutics Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Somatostatin Receptor Type 2 market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Somatostatin Receptor Type 2.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Somatostatin Receptor Type 2 Market by Company
Amryt Pharma plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Zucara Therapeutics Inc
Somatostatin Receptor Type 2 Segment by Type
CRN-00808
PRL-2903
Lanreotide Acetate
Others
Somatostatin Receptor Type 2 Segment by Application
Oncology
Hormonal Disorder
Metabolic Disorder
Others
Somatostatin Receptor Type 2 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin Receptor Type 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Somatostatin Receptor Type 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin Receptor Type 2.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Somatostatin Receptor Type 2 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CRN-00808
- PRL-2903
- Lanreotide Acetate
- Others
Applications
- Oncology
- Hormonal Disorder
- Metabolic Disorder
- Others
Companies covered
- Amryt Pharma plc
- Crinetics Pharmaceuticals Inc
- Daewoong Pharmaceutical Co Ltd
- Ipsen SA
- Progenics Pharmaceuticals Inc
- Strongbridge Biopharma plc
- Zucara Therapeutics Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Somatostatin Receptor Type 2 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 CRN-00808
- 2.2.3 PRL-2903
- 2.2.4 Lanreotide Acetate
- 2.2.5 Others
- 2.3 Somatostatin Receptor Type 2 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oncology
- 2.3.3 Hormonal Disorder
- 2.3.4 Metabolic Disorder
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Somatostatin Receptor Type 2 Breakdown Data by Type
- 3.1 Global Somatostatin Receptor Type 2 Historic Market Size by Type (2021-2026)
- 3.2 Global Somatostatin Receptor Type 2 Forecasted Market Size by Type (2027-2032)
4 Somatostatin Receptor Type 2 Breakdown Data by Application
- 4.1 Global Somatostatin Receptor Type 2 Historic Market Size by Application (2021-2026)
- 4.2 Global Somatostatin Receptor Type 2 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Somatostatin Receptor Type 2 Market Perspective (2021-2032)
- 5.2 Global Somatostatin Receptor Type 2 Growth Trends by Region
- 5.2.1 Global Somatostatin Receptor Type 2 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Somatostatin Receptor Type 2 Historic Market Size by Region (2021-2026)
- 5.2.3 Somatostatin Receptor Type 2 Forecasted Market Size by Region (2027-2032)
- 5.3 Somatostatin Receptor Type 2 Market Dynamics
- 5.3.1 Somatostatin Receptor Type 2 Industry Trends
- 5.3.2 Somatostatin Receptor Type 2 Market Drivers
- 5.3.3 Somatostatin Receptor Type 2 Market Challenges
- 5.3.4 Somatostatin Receptor Type 2 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Somatostatin Receptor Type 2 Players by Revenue
- 6.1.1 Global Top Somatostatin Receptor Type 2 Players by Revenue (2021-2026)
- 6.1.2 Global Somatostatin Receptor Type 2 Revenue Market Share by Players (2021-2026)
- 6.2 Global Somatostatin Receptor Type 2 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Somatostatin Receptor Type 2 Head Office and Area Served
- 6.4 Global Somatostatin Receptor Type 2 Players, Product Type & Application
- 6.5 Global Somatostatin Receptor Type 2 Manufacturers Established Date
- 6.6 Global Somatostatin Receptor Type 2 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Somatostatin Receptor Type 2 Market Size (2021-2032)
- 7.2 North America Somatostatin Receptor Type 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Somatostatin Receptor Type 2 Market Size by Country (2021-2026)
- 7.4 North America Somatostatin Receptor Type 2 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Somatostatin Receptor Type 2 Market Size (2021-2032)
- 8.2 Europe Somatostatin Receptor Type 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Somatostatin Receptor Type 2 Market Size by Country (2021-2026)
- 8.4 Europe Somatostatin Receptor Type 2 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Somatostatin Receptor Type 2 Market Size (2021-2032)
- 9.2 Asia-Pacific Somatostatin Receptor Type 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Somatostatin Receptor Type 2 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Somatostatin Receptor Type 2 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Somatostatin Receptor Type 2 Market Size (2021-2032)
- 10.2 South America Somatostatin Receptor Type 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Somatostatin Receptor Type 2 Market Size by Country (2021-2026)
- 10.4 South America Somatostatin Receptor Type 2 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Somatostatin Receptor Type 2 Market Size (2021-2032)
- 11.2 Middle East & Africa Somatostatin Receptor Type 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Somatostatin Receptor Type 2 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Somatostatin Receptor Type 2 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Amryt Pharma plc
- 12.1.1 Amryt Pharma plc Company Information
- 12.1.2 Amryt Pharma plc Business Overview
- 12.1.3 Amryt Pharma plc Revenue in Somatostatin Receptor Type 2 Business (2021-2026)
- 12.1.4 Amryt Pharma plc Somatostatin Receptor Type 2 Product Portfolio
- 12.1.5 Amryt Pharma plc Recent Developments
- 12.2 Crinetics Pharmaceuticals Inc
- 12.2.1 Crinetics Pharmaceuticals Inc Company Information
- 12.2.2 Crinetics Pharmaceuticals Inc Business Overview
- 12.2.3 Crinetics Pharmaceuticals Inc Revenue in Somatostatin Receptor Type 2 Business (2021-2026)
- 12.2.4 Crinetics Pharmaceuticals Inc Somatostatin Receptor Type 2 Product Portfolio
- 12.2.5 Crinetics Pharmaceuticals Inc Recent Developments
- 12.3 Daewoong Pharmaceutical Co Ltd
- 12.3.1 Daewoong Pharmaceutical Co Ltd Company Information
- 12.3.2 Daewoong Pharmaceutical Co Ltd Business Overview
- 12.3.3 Daewoong Pharmaceutical Co Ltd Revenue in Somatostatin Receptor Type 2 Business (2021-2026)
- 12.3.4 Daewoong Pharmaceutical Co Ltd Somatostatin Receptor Type 2 Product Portfolio
- 12.3.5 Daewoong Pharmaceutical Co Ltd Recent Developments
- 12.4 Ipsen SA
- 12.4.1 Ipsen SA Company Information
- 12.4.2 Ipsen SA Business Overview
- 12.4.3 Ipsen SA Revenue in Somatostatin Receptor Type 2 Business (2021-2026)
- 12.4.4 Ipsen SA Somatostatin Receptor Type 2 Product Portfolio
- 12.4.5 Ipsen SA Recent Developments
- 12.5 Progenics Pharmaceuticals Inc
- 12.5.1 Progenics Pharmaceuticals Inc Company Information
- 12.5.2 Progenics Pharmaceuticals Inc Business Overview
- 12.5.3 Progenics Pharmaceuticals Inc Revenue in Somatostatin Receptor Type 2 Business (2021-2026)
- 12.5.4 Progenics Pharmaceuticals Inc Somatostatin Receptor Type 2 Product Portfolio
- 12.5.5 Progenics Pharmaceuticals Inc Recent Developments
- 12.6 Strongbridge Biopharma plc
- 12.6.1 Strongbridge Biopharma plc Company Information
- 12.6.2 Strongbridge Biopharma plc Business Overview
- 12.6.3 Strongbridge Biopharma plc Revenue in Somatostatin Receptor Type 2 Business (2021-2026)
- 12.6.4 Strongbridge Biopharma plc Somatostatin Receptor Type 2 Product Portfolio
- 12.6.5 Strongbridge Biopharma plc Recent Developments
- 12.7 Zucara Therapeutics Inc
- 12.7.1 Zucara Therapeutics Inc Company Information
- 12.7.2 Zucara Therapeutics Inc Business Overview
- 12.7.3 Zucara Therapeutics Inc Revenue in Somatostatin Receptor Type 2 Business (2021-2026)
- 12.7.4 Zucara Therapeutics Inc Somatostatin Receptor Type 2 Product Portfolio
- 12.7.5 Zucara Therapeutics Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst